Breaking News

OctoPlus Inks Delivery Pact with U.S. Biotech

OctoPlus N.V. has signed an agreement with an undisclosed U.S. biotechnology company for the use of OctoPlus' controlled release technology.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

OctoPlus N.V. has signed an agreement with an undisclosed U.S. biotechnology company for the use of OctoPlus’ controlled release technology. OctoPlus will use its PolyActive drug delivery technology to develop a controlled release version of a product currently in clinical development. Simon Sturge, chief executive officer of OctoPlus, said, “I am delighted to see the continued adoption of our PolyActive technology. We continue to explore opportunities where OctoPlus’ uniqu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters